The value of carcinoembryonic antigen levels in non-small cell lung cancer patients treated with EGFR-TKI
Wenzhao ZHONG,Wei LI,Song DONG,Honghong YAN,Qiang NIE
DOI: https://doi.org/10.3978/j.issn.2095-6959.2015.06.017
2015-01-01
Abstract:Objective:hTe value of serum levels of carcinoembryonic antigen (CEA) were evaluated in non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib.Methods: Patient characteristics, histological and molecular profiles of advanced lung cancer patients who receiving gefitinib or erlotinib were retrospectively collected. Progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier and Cox regression models.Results: From June 2002 to August 2011, 209 patients with pathologically conifrmed locally advanced or metastatic NSCLC were enrolled into the study at Guangdong General Hospital (GGH). Patients in this study were retrospectively categorized into 3 groups as: group L (CEA≤5,n=54), group M (5<CEA≤20, n=52) and group H (CEA>20,n=103). The median PFS of group L, group M and group H was 19, 17 and 13 months (95% CI, 14.61-19.39;P=0.018); and the median OS of group L, group M and group H was 32, 31 and 24 months (95% CI, 25.14-30.86;P=0.010); the difference was statistically significant. Patients with low-CEA had signiifcantly longer PFS and OS. Elevated CEA with imaging ifnding progression at the same time in 45 cases, elevated CEA without imaging ifnding progression in 27 cases, the median PFS of two groups were 13 and 14 months (95% CI, 10.51-15.49;P=0.195); the median OS was 23 and 28 months (95% CI, 19.81-30.19;P=0.156). The patients of elevated CEA without imaging progression had a median PFS of 24.3 months (3 to 111 months).Conclusion: Pretreatment serum levels of CEA can serve as predictive and prognostic factor for advanced NSCLC patients treated with EGFR TKIs. CEA may be an alternative and useful indicator of treatment response. When CEA increased, imaging and symptoms should be also considered to determine treatment strategy.